StreetInsider.com News Articles

RedHill acquires Ferring's Rebyota and Clenpiq for $12M upfront

Tue, 01 Sep 2026 07:00:25 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced it has acquired exclusive commercialization rights to two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq, from Ferring Pharmaceuticals, according to a company statement dated September 1, 2026.

Under the terms of the agreement, RedHill paid $12 million upfront to Ferring, plus tiered royalties on net sales and potential future milestones. The upfront payment was funded through RedHill's previously announced $18 million divestiture of its Talicia product. RedHill received exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq.

The two products together generated approximately $37.5 million in 2025 U.S. net sales. Rebyota, a single-dose

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

Tue, 01 Sep 2026 07:00:00 -0400

Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill’s commercial GI business

The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

Tue, 01 Sep 2026 07:00:00 -0400

RedHill sells Talicia to Apotex for $18M upfront plus milestones

Mon, 31 Aug 2026 07:01:09 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) has divested its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for an upfront cash payment of $18 million, plus up to $35 million in additional payments tied to worldwide net sales milestones, according to a company statement.

Under the agreement, Apotex acquires RedHill's 70% interest in Talicia, an H. pylori treatment. The transaction follows Apotex's prior acquisition of Cumberland Pharmaceuticals Inc.'s U.S. branded business, which included Cumberland's 30% ownership stake in Talicia, giving Apotex full ownership of the product.

RedHill Chief Executive Officer Dror Ben-Asher said the deal converts the company's stake in

RedHill sells Talicia to Apotex for $18M upfront plus milestones

Mon, 31 Aug 2026 07:01:09 -0400

RedHill Chief Executive Officer Dror Ben-Asher said the deal converts the company's stake in

RedHill seeks Ebola treatment role for opaganib as cases top 3,200

Tue, 28 Jul 2026 07:02:32 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) reported that confirmed Bundibugyo ebolavirus cases have reached 3,221 with 1,407 deaths, as the company pursues development of its investigational drug opaganib as a potential treatment for Ebola virus disease (EVD).

According to a company statement dated July 28, 2026, RedHill is in discussions with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health, Mbarara University of Science and Technology (MUST), and the Scientific Advisory Committee of the Democratic Republic of Congo regarding potential partnerships and development next steps.

Professor Pauline Byakika-Kibwika, Vice Chancellor of MUST, said in the statement:

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths

Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee

Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Tue, 28 Jul 2026 07:00:00 -0400

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths
--
Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee
--
Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral

RedHill Biopharma closes $6M private placement with warrant upside

Mon, 22 Jun 2026 16:10:20 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced the closing of a private placement that raised approximately $6 million in upfront gross proceeds, with the potential for up to an additional $13.4 million if all warrants are exercised in full.

The offering involved the sale of 8,571,429 American Depositary Shares (ADSs), or ADS equivalents, at a combined purchase price of $0.70 per ADS. Each ADS represents 10,000 ordinary shares of the company. The placement also included two series of warrants, each covering up to 8,571,429 ADSs.

The Series A-1 warrants carry an exercise price of $0.86 per ADS, are immediately exercisable, and expire five

RedHill Biopharma closes $6M private placement with warrant upside

Mon, 22 Jun 2026 16:10:20 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced the closing of a private placement that raised approximately $6 million in upfront gross proceeds, with the potential for up to an additional $13.4 million if all warrants are exercised in full.

The offering involved the sale of 8,571,429 American Depositary Shares (ADSs), or ADS equivalents, at a combined purchase price of $0.70 per ADS. Each ADS represents 10,000 ordinary shares of the company. The placement also included two series of warrants, each covering up to 8,571,429 ADSs.

The Series A-1 warrants carry an exercise price of $0.86 per ADS, are immediately exercisable, and expire five

RedHill Biopharma closes $6M private placement with warrant upside

Mon, 22 Jun 2026 16:10:20 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced the closing of a private placement that raised approximately $6 million in upfront gross proceeds, with the potential for up to an additional $13.4 million if all warrants are exercised in full.

The offering involved the sale of 8,571,429 American Depositary Shares (ADSs), or ADS equivalents, at a combined purchase price of $0.70 per ADS. Each ADS represents 10,000 ordinary shares of the company. The placement also included two series of warrants, each covering up to 8,571,429 ADSs.

The Series A-1 warrants carry an exercise price of $0.86 per ADS, are immediately exercisable, and expire five

RedHill Biopharma closes $6M private placement with warrant upside

Mon, 22 Jun 2026 16:10:20 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced the closing of a private placement that raised approximately $6 million in upfront gross proceeds, with the potential for up to an additional $13.4 million if all warrants are exercised in full.

The offering involved the sale of 8,571,429 American Depositary Shares (ADSs), or ADS equivalents, at a combined purchase price of $0.70 per ADS. Each ADS represents 10,000 ordinary shares of the company. The placement also included two series of warrants, each covering up to 8,571,429 ADSs.

The Series A-1 warrants carry an exercise price of $0.86 per ADS, are immediately exercisable, and expire five

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

Mon, 22 Jun 2026 16:10:00 -0400

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants
TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

Mon, 22 Jun 2026 16:10:00 -0400

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants
TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

Mon, 22 Jun 2026 16:10:00 -0400

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants
TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the